In a report released today, Lyanne Harrison from Bank of America Securities maintained a Buy rating on Avita Medical (RCEL – Research Report). The company’s shares closed yesterday at $8.35.
According to TipRanks, Harrison is ranked #7533 out of 8805 analysts.
In addition to Bank of America Securities, Avita Medical also received a Buy from Lake Street’s Brooks O’Neil in a report issued today. However, on the same day, Piper Sandler maintained a Hold rating on Avita Medical (NASDAQ: RCEL).
The company has a one-year high of $21.70 and a one-year low of $7.97. Currently, Avita Medical has an average volume of 251.9K.
Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RCEL in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Avita Medical (RCEL) Company Description:
Avita Medical Ltd. engages in the development and distribution of regenerative and respiratory medicine and treatments. It operates through the following segments: Asia Pacific, Europe, and Americas. The Asia Pacific, Europe, and Americas segments involve in the sale of RECELL Devices. The company was founded on December 21, 1992 and is headquartered in Royston, the United Kingdom.
